Metformin + saxagliptin for type 2 diabetes

Bibliography

• Nathan DM, Buse JB, Davidson MB, Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2011. Diabetes Care 2011;34(Suppl 1):S11-61
   PubMed Web of Science ®Google Scholar
• Bennett WL, Maruthur NM, Singh S, Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-13
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA, Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
   PubMed Web of Science ®Google Scholar
• Shomali M. Add-on therapies to metformin for type 2 diabetes. Expert Opin Pharmacother 2011;12:47-62
   PubMed Web of Science ®Google Scholar
• Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother2011;13(1):81-99
   Google Scholar
• Adler AI, Shaw EJ, Stokes T, Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance. BMJ 2009;338:b1668
   Google Scholar
• Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010;122:71-80
   PubMed Web of Science ®Google Scholar
• Monami M, Iacomelli I, Marchionni N, Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010;20:224-35
   PubMed Web of Science ®Google Scholar
• Saxagliptin/metformin (Kombiglyze XR) for type 2 diabetes. Med Lett Drugs Ther 2011;53:21-2
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P. Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2011;4:263-71
   PubMedGoogle Scholar
• Scheen AJ. Saxagliptin and metformin combination therapy. Expert Rev Endocrinol Metab 2011; In press
   Google Scholar
• Boulton DW, Smith CH, Li L, Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects. Clin Drug Investig 2011;31:619-30
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab 2009;11:527-33
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Hissa MN, Garber AJ, The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-55
   PubMed Web of Science ®Google Scholar
• Yang W, Pan CY, To Efficacy and safety of saxagliptin added to metformin in Asian patients with type 2 diabetes mellitus: A randomized controlled trial. Diabetes Res Clin Pract 2011;94:217-24
   PubMed Web of Science ®Google Scholar
• DeFronzo R, Hissa M, Garbe al. Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with T2D. Diabetes 2009;58:A147- 547-P
   Google Scholar
• Fonseca V, Zhu T, Karyekar C, Adding saxagliptin (SAXA) 5 mg is superior to uptitrating metformin extended release (MET XR) in type 2 diabetes mellitus (T2DM) patients with inadequate glycemic control on a stable dose of MET XR 1500 mg. Diabetes 2011;60(Suppl 1):1018-P
   Google Scholar
• Hermans MP, Delibasi T, Farmer I, Effects of saxagliptin added to sub-maximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: results from the PROMPT study. Diabetologia 2011;54(Suppl 1):S337- 828
   Google Scholar
• Jadzinsky M, Pfutzner A, Paz-Pacheco E, Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-22
   PubMed Web of Science ®Google Scholar
• Pfutzner A, Paz-Pacheco E, Allen E, Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 2011;13:567-76
   PubMed Web of Science ®Google Scholar
• Gautier JF, Sauvanet JP. Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: Predictive factors of the treatment response in type 2 diabetes. Ann Endocrinol (Paris) 2011;72:287-95
   PubMedGoogle Scholar
• Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother 2010;8:405-18
   PubMed Web of Science ®Google Scholar
• Doucet J, Chacra A, Maheux P, Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin 2011;27:863-9
   PubMed Web of Science ®Google Scholar
• Boulton DW, Li L, Frevert EU, Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011;50:253-65
   PubMed Web of Science ®Google Scholar
• Nowicki M, Rychlik I, Haller H, Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011;13:523-32
   PubMed Web of Science ®Google Scholar
• Nowicki M, Rychlik I, Haller H, Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011;65:1230-9
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431-7
   PubMed Web of Science ®Google Scholar
• Kombiglyze XR (200678Orig1s000) at US Food and Drugs Administration. 2010. Available from: http://wwwaccessdatafdagov/drugsatfda_docs/nda/2010/200678Orig1s000Namepdf [Last accessed 17 November 2011]
   Google Scholar
• Kombiglyze at European Medicines Agency. Available from: http://wwwemaeuropaeu/ema/indexjsp?curl=pages/medicines/human/medicines/002059/smops/Positive/human_smop_000279jsp&mid=WC0b01ac058001d127&jsenabled=true [Last accessed 17 November 2011]
   Google Scholar
• Goke B, Gallwitz B, Eriksson J, Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trialInt J Clin Pract201064161931
   PubMed Web of Science ®Google Scholar
• Goke B, Gallwitz B, Eriksson J, Saxagliptin vs glipizide as add-on to metformin for type 2 diabetes mellitus (T2DM) : long-term safety and efficacy. Diabetes 2011;60(Suppl 1):1110-P
   Google Scholar
• Allen E, Berglind N. Saxagliptin vs glipizide as add-on therapy to metformin in patients with type 2 diabetes: a 2-year assessment of HbA1c, hypoglycaemia, and weight gain in a randomised, double-blind study. Diabetologia 2011;54(Suppl 1):S337-827
   Google Scholar
• Scheen AJ, Charpentier G, Ostgren CJ, Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010;26:540-9
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, Macconell L, Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9
   PubMed Web of Science ®Google Scholar
• Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 2011; In press
   Google Scholar
• DeFronzo RA, Okerson T, Viswanathan P, Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24:2943-52
   PubMed Web of Science ®Google Scholar
• Pratley R, Nauck M, Bailey T, One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011;65:397-407
   PubMed Web of Science ®Google Scholar
• Scheen AJ. DPP-4 inhibitors are favourable to GLP-1 receptor agonists: yes. Eur J Intern Med 2011; In press
   PubMedGoogle Scholar
• Charbonnel B, Barnett AH, Donovan M, Saxagliptin (SAXA) add-on therapy improves glycemic control in patients (pts) with poorly controlled type 2 diabetes (T2D) on insulin (INS) alone or INS combined with metformin (MET). Diabetes 2011;60(Suppl 1):1108-P
   Google Scholar
• Barnett AH, Charbonnel B, Li J, Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Diabetologia 2011;54(Suppl 1):S108-9. 243
   Google Scholar
• Migoya EM, Bergeron R, Miller JL, Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010;88:801-8
   PubMed Web of Science ®Google Scholar
• Elashoff M, Matveyenko AV, Gier B, Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6
   PubMed Web of Science ®Google Scholar
• Butler PC, Matveyenko AV, Dry S, Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia 2010;53:1-6
   PubMed Web of Science ®Google Scholar